Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

By sjmartinez • October 19, 2023

Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. PMID: 37855026; PMCID: PMC10579289.

Tags: ACTIV-2, covid-19, Infectious Diseases, Inhaled interferon, Publications, Randomized clinical trial, SARS-CoV-2

Design and evaluation of next-generation HIV genotyping for detection of resistance mutations to 28 antiretroviral drugs across five major classes including lenacapavir

Park SY, Takayama C, Ryu J, Sattah M, Badii Z, Kim JW, Shafer RW, Gorbach PM, Lee HY. Design and evaluation of next-generation HIV genotyping[...]

The Search for the Golden Egg: Applied Large Language Models to Detect Patients With Potential Exposure to Avian Influenza

Shenoy ES, Branch-Elliman W, Wiens J. The Search for the Golden Egg: Applied Large Language Models to Detect Patients With Potential Exposure to Avian Influenza.[...]

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial

Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard[...]